Rachel Vaknin - 05 Feb 2025 Form 4 Insider Report for Microbot Medical Inc. (MBOT)

Role: Chief Financial Officer
Signature: /s/ Rachel Vaknin
Issuer symbol: MBOT
Transactions as of: 05 Feb 2025
Net transactions value: $0
Form type: 4
Filing time: 07 Feb 2025, 16:30:17 UTC
Previous filing: 26 Feb 2024
Next filing: 20 Feb 2026
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MBOT	Stock Option (Right to Buy)	Award	$0	+48,125		$0.000000	48,125	05 Feb 2025	Common Stock, par value $0.01 per share	48,125	$2.04	Direct	F1
transaction	MBOT	Stock Option (Right to Buy)	Award	$0	+4,375		$0.000000	4,375	26 Feb 2024	Common Stock, par value $0.01 per share	4,375	$1.25	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on August 5, 2025, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan.
F2	Such options, granted on February 26, 2024, were performance-based options the vesting of which was subject to the satisfaction of milestones. On February 5, 2025, the Compensation Committee of the Board of Directors of the Issuer confirmed and determined that the milestones with respect to 4,375 options have been met and, accordingly, vested.

Content

The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on August 5, 2025, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan.

Such options, granted on February 26, 2024, were performance-based options the vesting of which was subject to the satisfaction of milestones. On February 5, 2025, the Compensation Committee of the Board of Directors of the Issuer confirmed and determined that the milestones with respect to 4,375 options have been met and, accordingly, vested.